FMP

FMP

Enter

ADAP - Adaptimmune Therapeu...

photo-url-https://images.financialmodelingprep.com/symbol/ADAP.png

Adaptimmune Therapeutics plc

ADAP

NASDAQ

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

0.663 USD

0.0134 (2.02%)

Balance Sheet

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Total Cash

89.54M

368.22M

369.58M

204.6M

146.94M

113.83M

214.96M

405.93M

766.56M

1.45B

Total Cash %

7.98k

9.3k

6.01k

753.67

243.76

100

100

100

100

Receivables

19.28M

139k

752k

7.43M

46.92M

50.31M

95M

179.39M

338.76M

639.72M

Receivables %

1.72k

3.51

12.23

27.39

77.83

44.19

44.19

44.19

44.19

Inventories

1.46M

2.09M

746k

1.28M

-

38.6M

72.89M

137.65M

259.94M

490.86M

Inventories %

130.04

52.7

12.13

4.71

-

33.91

33.91

33.91

33.91

Payable

6.36M

6.39M

8.11M

4.75M

8.13M

75.36M

142.3M

268.72M

507.45M

958.27M

Payable %

566.58

161.42

131.94

17.51

13.48

66.2

66.2

66.2

66.2

Cap Ex

-3.07M

-2.91M

-8.78M

-29.74M

-4.88M

-86.86M

-164.02M

-309.74M

-584.91M

-1.1B

Cap Ex %

-273.98

-73.42

-142.8

-109.55

-8.1

-76.3

-76.3

-76.3

-76.3

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep